Asbestos ban policies and mesothelioma mortality in Greece.
Asbestos-ban legislation
Epidemiology
Mesothelioma in Greece
Mortality rate
Public awareness
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
26 Apr 2024
26 Apr 2024
Historique:
received:
19
09
2023
accepted:
07
02
2024
medline:
27
4
2024
pubmed:
27
4
2024
entrez:
26
4
2024
Statut:
epublish
Résumé
Malignant mesothelioma is a rare form of cancer that mostly affects the pleura and has a strong link to asbestos exposure. Greece banned the use of asbestos in 2005, however, the public was already aware of this substance in the 1980s. This research aims to present an overview of Greece's mesothelioma age-standardized mortality rates (ASMR) from 1983 to 2019 by age, gender, and geographic region and to determine whether the actions to ban asbestos impacted these rates. Data were retrieved by the Hellenic Statistical Authority (HSA) from death certificates that mentioned mesothelioma as the cause of death from 1983 to 2019 with details on the residence, gender, and age. Statistical analysis was performed using PRISM 6.0 software, a two-way ANOVA test, Trend analysis was conducted using Joinpoint Regression Program 5.0 software. The linear and non-linear model was used to calculate the age-standardized rates of annual percentage change (APC) and its 95% confidential interval (95% CI). From 1983 to 2019, 850 total mesothelioma deaths were recorded, the majority of whom were males (634). A rate of 74.6% accounts for males and 25.4% for females, and the ratio of Males: Females was 3:1. Males' ASMR and the whole population's ASMR reached their highest levels in 2011 (0.93/100000person-years and 0.53/100000person-years, respectively). To look for potential changes between the first two decades of the 21st century, we compared the mean ASMR of each geographic region in Greece between two different 10-year subperiods (2000-2009 and 2010-2019). Except for Epirus, all regions of Greece had elevated regional ASMRs, particularly in those with the highest asbestos deposits. Notably, the ASMR in Epirus decreased from 0.54/100000person-years (2000-2009) to 0.31/100000person-years (2010-2019). After 2011, the ASMR for men and the general population stabilized. This stability is important since mesothelioma in men is associated with occupational asbestos exposure. The intriguing discovery of a lower ASMR in Epirus emphasizes the need to raise awareness of the condition and implement effective public health measures. In Greece, the annual ASMR for males and the whole population reached its highest level in 2011, which is positive and encouraging and may be a sign that the rate will stabilize during the following years. Moreover, this study showed that the actions made in the 1980s regarding public awareness and surveillance directly impacted the decrease in Epirus rates. Future research, continual awareness, information, and recording are needed to monitor the mesothelioma epidemic. The possible benefit of a mesothelioma registry and the epidemiological surveillance of asbestos-related diseases, particularly mesothelioma mortality, need to be addressed. Not applicable.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant mesothelioma is a rare form of cancer that mostly affects the pleura and has a strong link to asbestos exposure. Greece banned the use of asbestos in 2005, however, the public was already aware of this substance in the 1980s. This research aims to present an overview of Greece's mesothelioma age-standardized mortality rates (ASMR) from 1983 to 2019 by age, gender, and geographic region and to determine whether the actions to ban asbestos impacted these rates.
METHODS
METHODS
Data were retrieved by the Hellenic Statistical Authority (HSA) from death certificates that mentioned mesothelioma as the cause of death from 1983 to 2019 with details on the residence, gender, and age. Statistical analysis was performed using PRISM 6.0 software, a two-way ANOVA test, Trend analysis was conducted using Joinpoint Regression Program 5.0 software. The linear and non-linear model was used to calculate the age-standardized rates of annual percentage change (APC) and its 95% confidential interval (95% CI).
RESULTS
RESULTS
From 1983 to 2019, 850 total mesothelioma deaths were recorded, the majority of whom were males (634). A rate of 74.6% accounts for males and 25.4% for females, and the ratio of Males: Females was 3:1. Males' ASMR and the whole population's ASMR reached their highest levels in 2011 (0.93/100000person-years and 0.53/100000person-years, respectively). To look for potential changes between the first two decades of the 21st century, we compared the mean ASMR of each geographic region in Greece between two different 10-year subperiods (2000-2009 and 2010-2019). Except for Epirus, all regions of Greece had elevated regional ASMRs, particularly in those with the highest asbestos deposits. Notably, the ASMR in Epirus decreased from 0.54/100000person-years (2000-2009) to 0.31/100000person-years (2010-2019). After 2011, the ASMR for men and the general population stabilized. This stability is important since mesothelioma in men is associated with occupational asbestos exposure. The intriguing discovery of a lower ASMR in Epirus emphasizes the need to raise awareness of the condition and implement effective public health measures.
CONCLUSIONS
CONCLUSIONS
In Greece, the annual ASMR for males and the whole population reached its highest level in 2011, which is positive and encouraging and may be a sign that the rate will stabilize during the following years. Moreover, this study showed that the actions made in the 1980s regarding public awareness and surveillance directly impacted the decrease in Epirus rates. Future research, continual awareness, information, and recording are needed to monitor the mesothelioma epidemic. The possible benefit of a mesothelioma registry and the epidemiological surveillance of asbestos-related diseases, particularly mesothelioma mortality, need to be addressed.
TRIAL REGISTRATION
BACKGROUND
Not applicable.
Identifiants
pubmed: 38671450
doi: 10.1186/s12889-024-18030-x
pii: 10.1186/s12889-024-18030-x
doi:
Substances chimiques
Asbestos
1332-21-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1177Informations de copyright
© 2024. The Author(s).
Références
Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25(142):472–86. https://doi.org/10.1183/16000617.0063-2016
doi: 10.1183/16000617.0063-2016
pubmed: 27903668
pmcid: 9487555
Consonni D, Calvi C, Matteis S De, Mirabelli D, Landi MT, Caporaso NE, et al. Peritoneal mesothelioma and asbestos exposure: a population-based case– control study in Lombardy, Italy. Occup. Environ Med. 2019;76:545–53.
doi: 10.1136/oemed-2019-105826
pubmed: 31285358
Marinaccio A, Consonni D, Mensi C, Mirabelli D, Migliore E, Magnani C, et al. Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma: a case–control study and epidemiological remarks. Scand J Work Environ Health. 2020;46(6):609–17.
doi: 10.5271/sjweh.3895
pubmed: 32253443
pmcid: 7737812
Bridda A, Padoan I, Mencarelli R, and Frego M. Peritoneal mesothelioma: a review. MedGenMed. 2007;9(2):32.
pubmed: 17955087
pmcid: 1994863
Asciak R, George V, and Rahman NM. Update on biology and management of mesothelioma. Eur Respir Rev. 2021;30:200226. https://doi.org/10.1183/16000617.0226-2020
doi: 10.1183/16000617.0226-2020
pubmed: 33472960
pmcid: 9489032
Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, et al. Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18(6):792–802.
doi: 10.1016/j.jtho.2023.01.095
pubmed: 36775192
Forman D, Bray F, Brewster DH, Gombe MBalawa C, Kohler B, Pineros M, et al. Cancer incidence in five continents vol. X. IARC Scientific Publications. 2014;No 164.
Liu B, van Gerwen M, Bonassi S, and Taioli E. Epidemiology of environmental exposure and malignant mesothelioma. J Thorac Oncol. 2017;12(7):1031–45. https://doi.org/10.1016/j.jtho.2017.04.002
doi: 10.1016/j.jtho.2017.04.002
pubmed: 28412495
Noonan CW. Environmental asbestos exposure and risk of mesothelioma. Ann Transl Med. 2017;5(11):234.
doi: 10.21037/atm.2017.03.74
pubmed: 28706902
pmcid: 5497111
Alpert N, van Gerwen M, and Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28–38.
doi: 10.21037/tlcr.2019.11.11
pubmed: 32206568
pmcid: 7082259
Lin RT, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D, Kameda T, et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet. 2007;369:844–49.
doi: 10.1016/S0140-6736(07)60412-7
pubmed: 17350453
Carbone M, Yang H, Pass HI, and Taioli E. Did the ban on asbestos reduce the incidence of mesothelioma? J Thorac Oncol. 2023;18(6):694–97. https://doi.org/10.1016/j.jtho.2023.03.013
doi: 10.1016/j.jtho.2023.03.013
pubmed: 37210180
Zhai Z, Ruan J, Zheng Y, Xiang D, Li N, Hu J, et al. Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017. JAMA Network Open. 2021;4(8):e2120360.
doi: 10.1001/jamanetworkopen.2021.20360
pubmed: 34379126
pmcid: 8358735
Kumagai-Takei N, Lee S, Srinivas B, Shimizu Y, Sada N, Yoshitome K, et al. The effects of asbestos fibers on human T cells. Int J Mol Sci. 2020;21:6987. https://doi.org/10.3390/ijms21196987
doi: 10.3390/ijms21196987
pubmed: 32977478
pmcid: 7584019
Røe OD, and Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev. 2015;24:115–31. https://doi.org/10.1183/09059180.00007014
doi: 10.1183/09059180.00007014
pubmed: 25726562
pmcid: 9487774
Sporn TA. Mineralogy of asbestos. In: A. Tannapfel (ed.), Malignant mesothelioma, recent results in cancer research 189. 2011. https://doi.org/10.1007/978-3-642-10862-4_1
Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, and Roggli VL. Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med. 2018;142(6):753–60.
doi: 10.5858/arpa.2017-0365-RA
pubmed: 29480760
Loomis D, Richardson DB, and Elliott L. Quantitative relationships of exposure to chrysotile asbestos and mesothelioma mortality. Am J Ind Med. 2019;62(6):471–77. https://doi.org/10.1002/ajim.22985
doi: 10.1002/ajim.22985
pubmed: 31087402
pmcid: 6594234
Smith AH, and Wright CC. Chrysotile asbestos is the main cause of pleural mesothelioma. Am J Ind Med. 1996;30:252–66.
doi: 10.1002/(SICI)1097-0274(199609)30:3<252::AID-AJIM2>3.0.CO;2-0
pubmed: 8876792
Annals of the New York Academy of Sciences. Biological effects of asbestos. 1965;132(1):5–705. https://doi.org/10.1111/j.2164-0947.1965.tb02195.x
doi: 10.1111/j.2164-0947.1965.tb02195.x
IARC monographs on the evaluation of the carcinogenic risk to humans: asbestos. 1977;14. https://www.ncbi.nlm.nih.gov/books/NBK419324/
IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: silica and some silicates. 1987;42. https://www.ncbi.nlm.nih.gov/books/NBK410052/
IARC monographs on the evaluation of carcinogenic risks to humans: arsenic, metals, and dust. 2012;100 C.
Amand-Eeckhout L. EU legislation in progress: protection of workers from asbestos at work. Eur Parliam Res Serv Introd. 2023;PE 749.813.
Virta RL. Worldwide asbestos supply and consumption trends from1900 through 2003. US Geological Survey Circular. US Geological Survey Circular 1298. 2006;80p. https://doi.org/10.3133/cir1298
Laurie Kazan-Allen. London Asbestos meetings, April 2002. International ban Asbestos secretariat. 2002. http://ibasecretariat.org/lka_london_meetings_rep_0402.php (last accessed on 28 Dec 2023)
Laurie Kazan-Allen. Chronology of asbestos bans and restrictions. International Ban Asbestos Secretariat. 2023. http://ibasecretariat.org/chron_ban_list.php (last accessed on 28 Dec 2023)
Montanaro F, Bray F, Gennaro V, Merler E, Tyczynski JE, Parkin DM, et al. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes and Control. 2003;14:791–803.
doi: 10.1023/A:1026300619747
pubmed: 14674744
Van Kooten JP, Belderbos RA, Von Der Thüsen JH, Aarts MJ, Verhoef C, Burgers JA, et al. Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study. Thorax. 2022;77:1260–67.
doi: 10.1136/thoraxjnl-2021-217709
pubmed: 35149582
Thomas A, Karakattu S, Cagle J, and Hoskere G. Malignant pleural mesothelioma epidemiology in the United States from 2000 to 2016. Cureus. 2021;13(4):e14605. https://doi.org/10.7759/cureus.14605
doi: 10.7759/cureus.14605
pubmed: 34040906
pmcid: 8139608
Hemminki K, Försti A, Chen T, and Hemminki A. Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden. BMC Cancer. 2021;21:1189. https://doi.org/10.1186/s12885-021-08913-2
doi: 10.1186/s12885-021-08913-2
pubmed: 34749677
pmcid: 8576876
Gariazzo C, Gasparrini A, and Marinaccio A. Asbestos consumption and malignant mesothelioma mortality trends in the major user countries. Ann Glob Heal. 2023;89(1):11. https://doi.org/10.5334/aogh.4012
doi: 10.5334/aogh.4012
Burdorf A, Jarvholm B, and Englunt A. Explaining differences in incidence rates of pleural mesothelioma between Sweden and the Netherlands. Int J Cancer. 2005;113:298–301.
doi: 10.1002/ijc.20552
pubmed: 15386418
Zhu W, Liu J, Li Y, Shi Z, and Wei S. Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades. SSM - Popul Heal. 2023;23:101441. https://doi.org/10.1016/j.ssmph.2023.101441
doi: 10.1016/j.ssmph.2023.101441
Gogou E, Kerenidi T, Chamos V, Zintzaras E, and Gourgoulianis KI. Mesothelioma mortality in Greece from 1983 to 2003. Int J Clin Pract. 2009;63(6):944–8.
doi: 10.1111/j.1742-1241.2007.01334.x
pubmed: 17573841
Gogou E, Hatzoglou C, Zarogiannis SG, Malli F, Jagirdar RM, and Gourgoulianis KI. Mesothelioma mortality rates in Greece for the period 2005–2015 is increased compared to previous decades. Medicina. 2019;55(8):e419. https://doi.org/10.3390/medicina55080419
doi: 10.3390/medicina55080419
Virta, RL. Asbestos. U.S. Geological survey minerals yearbook 2007. 2008;8.1–8.6. http://minerals.usgs.gov/minerals/pubs/commodity/asbestos/myb1-2007-asbes.pdf (last accessed on December 30 2023)
Constantopoulos SH, Goudevenos JA, Saratzis N, Langer AM, Selikoff IJ, and Moutsopoulos HM. Metsovo lung: pleural calcification and restrictive lung function in northwestern Greece. Environmental exposure to mineral fiber as etiology. Environ Res. 1985;38(2):319–31.
doi: 10.1016/0013-9351(85)90096-9
pubmed: 4065080
Bazas T, Oakes D, Gilson JC, Bazas B, and McDonald JC. Pleural calcification in northwest Greece. Environ Res. 1985;38(2):239–47.
doi: 10.1016/0013-9351(85)90088-X
pubmed: 4065074
https://www.opendata.nhs.scot/dataset/standard-populations/resource/edee9731-daf7-4e0d-b525-e4c1469b8f69 . Standard Populations - European Standard Population (last accessed on 29 Dec 2023).
Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–96.
pubmed: 23977542
pmcid: 3741803
Scarselli A, Marinaccio A, and Iavicoli S. Ophiolitic outcrops, naturally occurring asbestos exposure and mortality risk from malignant mesothelioma in Calabria (Southern Italy). Public Health. 2021;195:57–60. https://doi.org/10.1016/j.puhe.2021.04.008
doi: 10.1016/j.puhe.2021.04.008
pubmed: 34052509
Torres-Roman JS, Gomez-Rubio V, Sanchez-Trujillo L, Delgado-Rosas E, Puche-Vergara F, Sanz-Anquela JM, et al. Geographic study of mortality due to mesothelioma in Peru and its evolution. Cancer Epidemiol. 2020;68:101791. https://doi.org/10.1016/j.canep.2020.101791
doi: 10.1016/j.canep.2020.101791
pubmed: 32823056
Metintas M, Metintas S, Ak G, Erginel S, Alatas F, Kurt E, et al. Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure. Respirology. 2008;13(1):117–21.
doi: 10.1111/j.1440-1843.2007.01187.x
pubmed: 18197921
Gogou E, Kerenidi T, Chamos V, Hatzoglou C, and Gourgoulianis KI. Environmental asbestos exposure alters the male: female ratio in patients with pleural mesothelioma. Respirology. 2008;13(6):931.
doi: 10.1111/j.1440-1843.2008.01373.x
pubmed: 18811894
Baur X, Frank AL, Soskolne CL, Oliver LC, and Magnani C. Malignant mesothelioma: ongoing controversies about its etiology in females. Am J Ind Med. 2021;64:543–50.
doi: 10.1002/ajim.23257
pubmed: 34036634
Gogou E, Zarogiannis SG, Siachpazidou D, Hatzoglou C, and Gourgoulianis KI. Causes and pathogenesis of malignant mesothelioma. In: Strumfa I (editor) Mesothelioma - diagnostics, treatment and basic research. IntechOpen. 2022. https://doi.org/10.5772/intechopen.103669
Mazurek JM, Syamlal G, Wood JM, Hendricks SA, and Weston A. Malignant mesothelioma mortality — United States, 1999–2015. MMWR. 2017;66(8):214–8.
pubmed: 28253224
pmcid: 5657894
Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, and Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89:716–24C. https://doi.org/10.2471/BLT.11.086678
doi: 10.2471/BLT.11.086678
pubmed: 22084509
pmcid: 3209980
Newhouse ML, and Berry G. Predictions of mortality from mesothelial tumours in asbestos factory workers. British J Industrial Medicine. 1976;33:147–51.
Peto J, Seidman H, and Selikoff IJ. Mesothelioma in asbestos workers: implications for models of carcinogenesis and risk assessment. Br J Cancer. 1982;45:124–35.
doi: 10.1038/bjc.1982.15
pubmed: 7059455
pmcid: 2010947
Berry G, de Klerk NH, Reid A, Ambrosini GL, Fritschi L, N J Olsen NJ, et al. Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia. Occup Env Med. 2004;61:e14. http://www.occenvmed.com/cgi/content/full/61/4/e14 (last accessed on 17 Dec 2023).
doi: 10.1136/oem.2003.008128
McDonald JC, Harris JM, and Berry G. Sixty years on: the price of assembling military gas masks in 1940. Occup Env Med. 2006;63:852–55.
doi: 10.1136/oem.2006.028258
Harding AH, and Darnton AJ. Asbestosis and mesothelioma among British Asbestos workers (1971–2005). Am J Ind Med. 2010;53:1070–80.
doi: 10.1002/ajim.20844
pubmed: 20957726
Luberto F, Ferrante D, Silvestri S, Angelini A, Cuccaro F, Nannavecchia AM, et al. Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy. Environ Health. 2019;18:71. https://doi.org/10.1186/s12940-019-0510-6 (last accessed on 17 Dec 2023).
doi: 10.1186/s12940-019-0510-6
pubmed: 31391078
pmcid: 6686495
Segura O, Burdorf A, and Looman C. Update of predictions of mortality from pleural mesothelioma in the Netherlands. Occup Environ Med. 2003;60:50–55.
doi: 10.1136/oem.60.1.50
pubmed: 12499457
pmcid: 1740374
Peto J, Decarli A, La Vecchia C, Levi F, and Negri E. The European mesothelioma epidemic. British J Cancer. 1999;79(3/4):666–72.
doi: 10.1038/sj.bjc.6690105
Fazzo L, Binazzi A, Ferrante D, Minelli G, Consonni D, Bauleo L, et al. Burden of mortality from asbestos-related diseases in italy. Int J Environ Res Public Health. 2021;18:10012. https://doi.org/10.3390/ijerph181910012 (last accessed on 3 May 2023).
Oddone E, Bollon J, Nava CR, Consonni D, Marinaccio A, Magnani C, et al. Effect of asbestos consumption on malignant pleural mesothelioma in Italy: forecasts of mortality up to 2040. Cancers. 2021;13:3338. https://doi.org/10.3390/cancers13133338 (last accessed on 2 May 2023).
doi: 10.3390/cancers13133338
pubmed: 34283067
pmcid: 8267929
Soeberg MJ, Leigh J, and van Zandwijk N. Malignant mesothelioma in Australia 2015: current incidence and asbestos exposure trends. J Toxicol Environ Health - Part B Crit Rev. 2016;19(5–6):173–89. https://doi.org/10.1080/10937404.2016.1194254
doi: 10.1080/10937404.2016.1194254
Algranti E, Santana VS, Campos F, Salvi L, Saito CA, Cavalcante F, et al. Analysis of mortality from asbestos-related diseases in Brazil using multiple health information systems, 1996–2017. Saf Health Work. 2022;13:302–7. https://doi.org/10.1016/j.shaw.2022.04.006
doi: 10.1016/j.shaw.2022.04.006
pubmed: 36156859
pmcid: 9482009
Marinaccio A, Corfiati M, Binazzi A, Di Marzio D, Scarselli A, Ferrante P, et al. The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure. Occup Environ Med. 2018;75:254–62.
doi: 10.1136/oemed-2016-104119
pubmed: 29269563
Carbone M, Yang H, Pass HI, Krausz T, Testa JR, and Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13(3):153–59.
doi: 10.1038/nrc3459
pubmed: 23550303
pmcid: 3792854
Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, et al. Consensus report of the 2015 Weinman international conference on mesothelioma. J Thorac Oncol. 2016;11(8):1246–62.
Panou V, and Røe OD. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int J Mol Sci. 2020;21(12):4327.
doi: 10.3390/ijms21124327
pubmed: 32560575
pmcid: 7352726
Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol. 2018;36(35):3485–94.
doi: 10.1200/JCO.2018.79.0352
pmcid: 7162737
Kato S, Tomson BN, Buys TPH, Elkin SK, Carter JL, and Kurzrock R. Genomic landscape of malignant mesotheliomas. Mol Cancer Ther. 2016;15(10):2498–507.
doi: 10.1158/1535-7163.MCT-16-0229
pubmed: 27507853
Betti M, Aspesi A, Sculco M, Matullo G, Magnani C, and Dianzani I. Genetic predisposition for malignant mesothelioma: a concise review. Mutat Res - Rev Mutat Res. 2019;781:1–10. https://doi.org/10.1016/j.mrrev.2019.03.001
doi: 10.1016/j.mrrev.2019.03.001
pubmed: 31416570
Taioli E, Wolf AS, Camacho-Rivera M, and Flores RM. Women with malignant pleural mesothelioma have a threefold better survival rate than men. Ann Thorac Surg. 2014;98(3):1020–24. https://doi.org/10.1016/j.athoracsur.2014.04.040
doi: 10.1016/j.athoracsur.2014.04.040
pubmed: 24928677
Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76–81.
doi: 10.1093/carcin/bgu227
pubmed: 25380601
Sakellariou K, Malamou-Mitsi V, Haritou A, Koumpaniou C, Stachouli C, Dimoliatis ID, et al. Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic? Eur Respir J. 1996;9(6):1206–10.
doi: 10.1183/09031936.96.09061206
pubmed: 8804939